Empagliflozin Superior to Placebo for Heart Failure
WEDNESDAY, Sept. 2, 2020 -- Among patients with heart failure, risk for cardiovascular death or hospitalization with heart failure is lower for those receiving empagliflozin compared with placebo, according to a study published online Aug. 29 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 2, 2020 Category: Pharmaceuticals Source Type: news

SGLT2 Inhibitors in HFrEF: Putting EMPEROR-Reduced in Context SGLT2 Inhibitors in HFrEF: Putting EMPEROR-Reduced in Context
Dr Ileana Pi ñ a asks the lead investigator how his trial on empagliflozin in HFrEF compares with DAPA-HF. They speculate on the likely mechanism of action of these relatively new drugs.theheart.org on Medscape (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 1, 2020 Category: Intensive Care Tags: Cardiology Commentary Source Type: news

Empagliflozin's HFrEF Benefit Solidifies Class Effects Empagliflozin's HFrEF Benefit Solidifies Class Effects
The 25% cut in primary endpoints among patients with HFrEF receiving empagliflozin in EMPEROR-Reduced matched the benefit seen before from dapagliflozin in DAPA-HF.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 30, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Positive Top-line Results for Another SGLT2 Inhibitor in HF Positive Top-line Results for Another SGLT2 Inhibitor in HF
Empagliflozin reduced the risk of CV death or heart failure hospitalization in a phase 3 trial of adults with HF and reduced ejection fraction.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 31, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Jardiance(R) meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes
Jardiance (empagliflozin) significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction ... Biopharmaceuticals, Endocrinology Eli Lilly, Jardiance, empagliflozin, diabetes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 30, 2020 Category: Pharmaceuticals Source Type: news

Empagliflozin 2nd-line therapy in T2DM: better outcomes, lower cost in US
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2020 Category: Drugs & Pharmacology Source Type: news

EMPA-REG OUTCOME: Empagliflozin Cuts Insulin Need in Type 2 Diabetes EMPA-REG OUTCOME: Empagliflozin Cuts Insulin Need in Type 2 Diabetes
The SGLT2 inhibitor reduced the need to start insulin treatment or intensify existing insulin treatment compared with placebo in a post-hoc analysis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Trijardy XR (Empagliflozin, Linagliptin, and Metformin Hydrochloride Extended-release Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 14, 2020 Category: Drugs & Pharmacology Source Type: news

Trijardy XR (Empagliflozin, Linagliptin, and Metformin Hydrochloride Extended-release Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 5, 2020 Category: Drugs & Pharmacology Source Type: news

Monthly News Roundup - January 2020
Trijardy XR: A Triple Drug Combo Approved for Type 2 Diabetes In January, the US Food and Drug Administration (FDA) approved once-daily Trijardy XR (empagliflozin, linagliptin, and metformin hydrochloride extended release tablets) to lower blood... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 31, 2020 Category: Pharmaceuticals Source Type: news

FDA OKs New Triple-Combo Pill, Trijardy XR, for Type 2 Diabetes FDA OKs New Triple-Combo Pill, Trijardy XR, for Type 2 Diabetes
The once-daily treatment comprises empagliflozin (Jardiance), linagliptin (Tradjenta), and extended-release metformin hydrochloride. It will be available in four different dosages.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 28, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA Approves Trijardy XR (empagliflozin/linagliptin/metformin) for Type 2 Diabetes in Adults
RIDGEFIELD, Conn., and INDIANAPOLIS, Jan. 27, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride extended release tablets) to lower blood sugar in adults with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 28, 2020 Category: Drugs & Pharmacology Source Type: news

Lilly, Boehringer's Jardiance has heart failure trial setback
Boehringer Ingelheim and Eli Lilly announced failing results in two trials evaluating Jardiance in adults with chronic heart failure. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 13, 2019 Category: Pharmaceuticals Source Type: news

FDA Panel Rejects Empagliflozin for Use in Type 1 Diabetes FDA Panel Rejects Empagliflozin for Use in Type 1 Diabetes
The FDA advisers said the pivotal approval study was too short and did not involve enough patients to characterize efficacy or safety.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 14, 2019 Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology News Source Type: news

' Best in Class' Diabetes Drugs Compared in Head-to-Head Trial'Best in Class' Diabetes Drugs Compared in Head-to-Head Trial
A1c was reduced significantly more with oral semaglutide versus empagliflozin in a comparison of the type 2 diabetes drugs, but the former still lacks evidence of CV efficacy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 11, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Empagliflozin in T2DM: long-term benefits at acceptable costs
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2019 Category: Drugs & Pharmacology Source Type: news

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
Fast Track designation facilitates development of new therapies that treat serious conditions and fulfill an unmet medical need FDA's Fast Track designation for empagliflozin underscores the urgent need for new potential treatment options for the 6.5 mi... Biopharmaceuticals, Cardiology, FDA Eli Lilly, Boehringer Ingelheim, empagliflozin, JARDIANCE, heart failure (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 26, 2019 Category: Pharmaceuticals Source Type: news

FDA-fast-track-designation-chronic-heart-failure
US FDA grants Fast Track designation to empagliflozin for the treatment of chronic heart failureFast Track designation facilitates the development of new therapies that treat serious conditions and fulfill an unmet medical need.  FDA ’s Fast Track designation for empagliflozin underscores the urgent need for new potential treatment options for the 26 million people affected by chronic heart failure worldwide, including 6.5 million in the US.1,2 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 26, 2019 Category: Research Source Type: news

Effects of Empagliflozin on Metabolic Parameters in PCOS Effects of Empagliflozin on Metabolic Parameters in PCOS
In what ways might treatment with empagliflozin impact the metabolic parameters in women with PCOS?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 12, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

type-2-diabetes-cardiorenal-post-hoc-analysis
New post-hoc analysis shows consistent cardiorenal risk reductions of empagliflozin in a sub-group of adults with type 2 diabetes and chronic kidney disease without overt proteinuriaFindings from a post-hoc analysis of the EMPA-REG OUTCOME ® trial in adults with type 2 diabetes and chronic kidney disease without overt proteinuria were presented at the 79th American Diabetes Association Scientific Sessions® (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 10, 2019 Category: Research Source Type: news

effectiveness-analysis-in-diabetic-kidney-disease-and-type-2-diabetes
New post-hoc analysis of EMPA-REG OUTCOME ® examined cost-effectiveness of empagliflozin versus standard of care in a subgroup of people with type 2 diabetes and diabetic kidney disease Empagliflozin, in addition to standard of care, has the potential to improve economic outcomes for people with type 2 diabetes and established cardiovascular disease who also have diabetic kidney disease, from a US payer perspective1  Cost effective analysis used modeling and simulations based on subgroup data from EMPA-REG OUTCOME ® to predict clinical events and estimated costs for people with type 2 diabetes and diabeti...
Source: Boehringer Ingelheim Corporate News - April 15, 2019 Category: Research Source Type: news

EMPRISE real-world study results
Initial results from the EMPRISE real-world study of empagliflozin compared with DPP-4 inhibitors presented at ACC.19 and AMCP 2019  EMPRISE is an ongoing real-world evidence study in 35,000 people with type 2 diabetes in the US, comparing empagliflozin with DPP-4 inhibitors; initial results based on the first two years of the study were presented at AMCP 2019 and ACC.191,2Initial results presented at AMCP 2019 showed empagliflozin was associated with reductions in all-cause hospitalisations compared with DPP-4 inhibitors, and significantly fewer recurrent emergency department visits and physician office visits1Initia...
Source: Boehringer Ingelheim Corporate News - March 28, 2019 Category: Research Source Type: news

Empa ACC Expert Consensus Decision Pathway
American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert Consensus Decision Pathway (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 23, 2018 Category: Research Source Type: news

Empagliflozin May Reduce LV Mass in Patients With CVD, Diabetes Empagliflozin May Reduce LV Mass in Patients With CVD, Diabetes
EMPA-HEART Cardiolink-6 trial results suggest that the SGLT2 inhibitor is linked to reduced left ventricular mass, a surrogate for reduced heart failure, in patients with CVD and type 2 diabetes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 13, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Study suggests diabetes medication improves heart structure
(St. Michael's Hospital) The diabetes medication empagliflozin has important effects that can improve cardiac structure in people with Type 2 diabetes who also have heart disease, suggests a new study led by St. Michael's Hospital. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 12, 2018 Category: International Medicine & Public Health Source Type: news

AHA: Reverse Remodeling Plays Role in Jardiance CV Benefit
(MedPage Today) -- Data show empagliflozin-associated LV remodeling (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - November 11, 2018 Category: Pediatrics Source Type: news

Initial results from EMPRISE real-world evidence study shows empagliflozin was associated with reduced risk for hospitalisation for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
Empagliflozin was associated with a 44 percent reduction in relative risk of hospitalization for heart failure (HHF) compared with commonly used dipeptidyl peptidase-4 inhibitors1Effect of empagliflozin on HHF was consistent in patients with and without established cardiovascular disease1Findings support data from the landmark EMPA-REG OUTCOME ® trial, in which empagliflozin reduced the relative risk of HHF by 35 percent in people with type 2 diabetes and established cardiovascular disease2 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 5, 2018 Category: Research Source Type: news

Individual stress susceptibility and glucose metabolism are linked to brain function
(Johannes Gutenberg Universitaet Mainz) Researchers at the Department for Psychiatry and Psychotherapy at the Mainz University Medical Center and the German Resilience Center (DRZ) in Mainz have now discovered that stress-induced mental disturbances in mice are directly linked to abnormal glucose metabolism. Normalizing the stress-induced alterations in glucose levels, using the anti-diabetic drug empagliflozin, restored spatial memory as well as long-term glucose metabolism. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 24, 2018 Category: International Medicine & Public Health Source Type: news

EASE: Empagliflozin Beneficial in Type 1 Diabetes, DKA a Risk EASE: Empagliflozin Beneficial in Type 1 Diabetes, DKA a Risk
Speakers at EASD present divergent risk-benefit analyses for use of SGLT2 inhibitors in type 1 diabetes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 11, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes
All investigated doses met the primary efficacy endpoint defined as a change from baseline in A1C versus placebo after 26 weeks of treatment Regulatory discussions initiated for empagliflozin, as adjunct to insulin, in type 1 diabetes Full results pr... Biopharmaceuticals, Endocrinology Boehringer Ingelheim, Eli Lilly, empagliflozin, EASE-2 study, diabetes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 4, 2018 Category: Pharmaceuticals Source Type: news

Empa T1D Full Data
Boehringer Ingelheim and Lilly present full results from EASE Phase III programme for empagliflozin as adjunct to insulin in type 1 diabetesAll investigated doses met the primary efficacy endpoint defined as a change from baseline in HbA1c versus placebo after 26 weeks of treatment  Regulatory discussions initiated for empagliflozin, as adjunct to insulin, in type 1 diabetes  Full results presented at the 54th European Association for the Study of Diabetes Annual Congress (EASD) and published online in Diabetes Care ahead of print1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 4, 2018 Category: Research Source Type: news

Empa long-term survival benefit
New analysis estimates the positive impact of empagliflozin on prolonging life expectancy in adults with type 2 diabetes and established cardiovascular diseaseSurvival estimates from the EMPA-REG OUTCOME ® trial data demonstrate potential long-term benefit of empagliflozin (marketed as Jardiance®) on life expectancy of adults with type 2 diabetes and cardiovascular disease1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 25, 2018 Category: Research Source Type: news

How One Class Of Diabetes Medications May Lead To Flesh-Eating Genital Infections
If you are taking canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, or any other sodium-glucose cotransporter-2 (SGLT2) inhibitor, you may want to pay attention to this FDA warning. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 1, 2018 Category: Pharmaceuticals Authors: Bruce Y. Lee, Contributor Source Type: news

Empagliflozin Doesn't Up Risk of Bone Fractures
FRIDAY, July 20, 2018 -- Empagliflozin does not increase the risk of bone fracture in patients with type 2 diabetes, according to a study published online June 15 in Diabetes Care. Sven Kohler, M.D., from Boehringer Ingelheim International in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 20, 2018 Category: Pharmaceuticals Source Type: news

Highmark, pharmaceutical company reach deal on diabetes drug
Jardiance is prescribed for people with latter stages of Type 2 diabetes that also have cardiovascular disease. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 10, 2018 Category: American Health Authors: Paul J. Gough Source Type: news

Highmark, pharmaceutical company reach deal on diabetes drug
Jardiance is prescribed for people with latter stages of Type 2 diabetes that also have cardiovascular disease. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 10, 2018 Category: Biotechnology Authors: Paul J. Gough Source Type: news

Highmark, pharmaceutical company reach deal on diabetes drug
Jardiance is prescribed for people with latter stages of Type 2 diabetes that also have cardiovascular disease. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 10, 2018 Category: American Health Authors: Paul J. Gough Source Type: news

Lilly's Jardiance Meets Main Goal in Type 1 Diabetes Patients Lilly's Jardiance Meets Main Goal in Type 1 Diabetes Patients
Eli Lilly& Co said on Monday that its drug Jardiance (empagliflozin), along with insulin therapy, met the main goal of two trials testing it in patients with type 1 diabetes, a population for which it is not presently approved.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 25, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Lilly's Jardiance meets main goal of two diabetes trials
(Reuters) - Eli Lilly& Co said on Monday that its drug Jardiance, along with insulin therapy, met the main goal of two trials testing it in patients with type 1 diabetes. (Source: Reuters: Health)
Source: Reuters: Health - June 25, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Empagliflozin cost effective for T2D + CV disease in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2018 Category: Drugs & Pharmacology Source Type: news

Novo Nordisk oral diabetes drug outperforms Lilly rival
The company's oral diabetes drug semaglutide was found to be better at lowering blood sugar levels than Jardiance from Eli Lilly and Boehringer Ingelheim (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 29, 2018 Category: Pharmaceuticals Source Type: news

Novo Nordisk's oral diabetes drug beats Jardiance in study
LONDON (Reuters) - An experimental diabetes pill from Novo Nordisk proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim's established Jardiance in a clinical study, the Danish drugmaker said on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - May 29, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) have announced an academic collaboration with the University of Oxford. EMPA-KIDNEY will investigate the effects of empagliflozin on the progression of kidney disease and the occurrence of cardiovascular death, in people with established chronic kidney disease with and without diabetes. (Source: World Pharma News)
Source: World Pharma News - April 16, 2018 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Empagliflozin Trims Liver Fat in Patients With T2D and NAFLD Empagliflozin Trims Liver Fat in Patients With T2D and NAFLD
Dr Kuchay discusses his findings from the E-LIFT study.Endocrine Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 9, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news

Empagliflozin Eyed for Fatty Liver Disease in Type 2 Diabetes Empagliflozin Eyed for Fatty Liver Disease in Type 2 Diabetes
The first trial of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes and nonalcoholic fatty liver disease indicates the drug might reduce liver fat, but the results of the small study need replication.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 22, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Empagliflozin Survival Benefit in Diabetes: Is it Plasma Volume Drop? Empagliflozin Survival Benefit in Diabetes: Is it Plasma Volume Drop?
Changes in hematocrit and hemoglobin accounted for half the effect on CV death seen with empagliflozin in patients with type 2 diabetes in EMPA-REG Outcome, a new analysis confirms.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 1, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Empagliflozin good value for money for T2DM in Greece
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2018 Category: Drugs & Pharmacology Source Type: news

Boehringer Ingelheim inks outcomes-based contract with pharmacy benefit manager for diabetes drug
Boehringer Ingelheim has inked an outcomes-based contract with pharmacy benefit manager Prime Therapeutics for its oral Type II diabetes drug, Jardiance. The medication is designed to cut the risk of cardiovascular death in adult patients with Type II diabetes and established heart disease. Get the full story at our sister site, Drug Delivery Business News. The post Boehringer Ingelheim inks outcomes-based contract with pharmacy benefit manager for diabetes drug appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 29, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Diabetes Pharmaceuticals Boehringer Ingelheim Pharmaceuticals Source Type: news

Plasma Volume Changes May Mediate Effects of Empagliflozin
Findings suggest reduced CV mortality risk mediated by effects on markers of plasma volume (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - December 26, 2017 Category: Respiratory Medicine Tags: Cardiology, Endocrinology, Family Medicine, Geriatrics, Gynecology, Internal Medicine, Critical Care, Nursing, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news

Empagliflozin Particularly Effective in'Vulnerable' Diabetes Subgroup Empagliflozin Particularly Effective in'Vulnerable' Diabetes Subgroup
Empagliflozin reduced cardiac death with no signal of increased risk of amputation in patients with type 2 diabetes and PAD in EMPA-REG, with an NNT that was lower than for the trial population as a whole.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - November 28, 2017 Category: Endocrinology Tags: Cardiology News Source Type: news